New prostate cancer trial aims to cut fatigue with personalized drug plan
NCT ID NCT06274047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether personalizing apalutamide treatment based on cancer aggressiveness can reduce fatigue and other side effects in men with prostate cancer who have detectable PSA after prostatectomy. About 120 participants will receive either standard therapy or a personalized apalutamide regimen alongside radiation and hormone therapy. The goal is to improve quality of life without compromising cancer control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apalutamide and androgen deprivation therapy (ADT)
What this could lead to
If successful, this could lead to a more personalized treatment approach that reduces fatigue and other side effects for men with prostate cancer after surgery and radiation.
What could go wrong
This is a Phase 3 trial, but it is still experimental. The personalized approach may not improve quality of life as hoped, and side effects from apalutamide and ADT can still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
-
Rush MD Anderson
RECRUITINGChicago, Illinois, 60607, United States
Contact Email: •••••@•••••
Contact
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66103, United States
Contact Email: •••••@•••••
Contact